Magnus Jaderberg
Chief Tech/Sci/R&D Officer bij Targovax Oy
Profiel
Magnus Jaderberg is currently working as a Principal at Karolinska Institutet, an Honorary Lecturer at King's College (Pennsylvania), a Principal at The Royal College of Physicians, and as the Chief Medical Officer at Targovax Oy.
Previously, he worked as the Chief Medical Officer-Europe at Bristol Myers Squibb Co. and as the Chief Medical Officer at Circio Holding ASA.
Actieve functies van Magnus Jaderberg
| Bedrijven | Functie | Begin |
|---|---|---|
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Chief Tech/Sci/R&D Officer | - |
| King's College (Pennsylvania) | Corporate Officer/Principal | - |
| Karolinska Institutet | Corporate Officer/Principal | - |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Eerdere bekende functies van Magnus Jaderberg
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| CIRCIO HOLDING ASA | Chief Tech/Sci/R&D Officer | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CIRCIO HOLDING ASA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
